)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Tenax Therapeutics
Tenax Therapeutics (TENX) investor relations material
Tenax Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Phase 3 LEVEL missed its primary 6-minute walk distance and key secondary symptom-score endpoints overall; subgroup analyses showed exercise and biomarker benefits.
Post hoc analyses informed an enrollment-enrichment amendment for LEVEL-2; enrollment is temporarily paused while sites implement narrower criteria.
Financial highlights
Q3 operating expenses were $17.7M, up 5% YoY; net loss was $16.7M vs. $15.8M, and loss per share was $0.31 vs. $0.40.
Q3 R&D was $12.1M vs. $10.3M, while SG&A was $5.7M vs. $6.5M; higher clinical and preclinical costs drove R&D growth, while lower stock-based compensation reduced SG&A.
Nine-month operating expenses were $53.1M vs. $39.9M; net loss was $50.2M vs. $37.1M and loss per share was $1.01 vs. $0.96. R&D rose 65% to $36.5M; SG&A fell 7% to $16.6M.
Outlook and guidance
Cash is expected to fund operations through FY2028 under the current plan, assuming the amended LEVEL-2 design and no additional trials; the outlook may change after FDA discussions.
A Type C FDA meeting will address levosimendan’s development; a development update and LEVEL-2 design paper are expected in Q1 2027.
LEVEL-2 enrollment is expected to resume as sites implement the amendment; SG&A is expected to rise as development advances toward potential commercialization.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Tenax Therapeutics
- Future trials will enroll sicker patients to better capture strong clinical and biomarker effects.TENX
12th Annual Cantor Fitzgerald Global Healthcare Conference - LEVEL Phase 3 showed 49% NT-proBNP reduction and functional benefit in sicker patients.TENXStudy result
- Q2 2026 net loss rose 64% year-over-year as R&D spending surged for Phase 3 trials.TENXQ2 2026
- LEVEL phase III study targets 230 enrollments by 1H next year, with global expansion in LEVEL 2.TENXPiper Sandler 37th Annual Healthcare Conference
- Q1 2026 net loss rose to $15.7M as Phase 3 trials advanced, with cash at $118.8M.TENXQ1 2026
- Director elections and auditor ratification headline the June 2026 annual meeting agenda.TENXProxy filing
- Annual meeting to elect directors, ratify auditor, and review governance and compensation.TENXProxy filing
- Seeks to raise up to $300 million for late-stage cardiopulmonary drug development via shelf registration.TENXRegistration filing
- LEVEL trial enrollment finished early; global expansion and Q3 results expected.TENXLeerink Global Healthcare Conference 2026
Next Tenax Therapeutics earnings date
Q4 202610 Mar, 2027
Tenax Therapeutics
Next Tenax Therapeutics earnings date
Q4 202610 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Tenax Therapeutics Inc is a U.S.-based pharmaceutical company engaged in the development of therapies for cardiovascular and pulmonary diseases. The company focuses on late-stage clinical development and regulatory advancement of drug candidates aimed at addressing unmet medical needs in rare conditions. It operates within the biotechnology sector and collaborates with research institutions and clinical networks. The company is headquartered in Chapel Hill, North Carolina, and its shares are listed on the NASDAQ.